From the Rezilir Health clinical team. May 2026.
Why we wrote this
Most weeks, someone sits down in our office with a news clipping in their hand. Sometimes it’s about a new Alzheimer’s drug. Sometimes it’s a piece that says a weight-loss drug prevents dementia. Sometimes it’s a Long COVID article, or a menopause-and-memory thread, or an air pollution map that just made them afraid of their own commute.
The clippings are rarely wrong, but they are almost always missing the part that matters most to the person reading them: does this apply to me, how big is the effect actually, and what should I do differently starting now. AI has made the data easier to find, but it has not made the judgment easier.
That is where Rezilir Health comes in.
The last twelve months were an unusually productive year in the cognitive decline research world. Two major studies of anti-amyloid drugs came out the same month and appeared, at first, to contradict each other.
A real-world comparison of two weight-loss-and-diabetes drugs on memory-loss risk produced numbers that were hard to take at face value and hard to ignore. Long COVID cognition, which many hoped would quietly resolve on its own, got a study that closed that door.
Three separate research groups produced hard data for something we’ve believed clinically for a decade: that chronic inflammation in the brain is doing most of the work in cognitive decline.
Hormones finally got brain-imaging evidence, air pollution got genetics-stratified data, and a type of AI that combines blood tests, imaging, and cognitive scores stopped being a conference slide and became a real clinical tool.
Finally, the EVANTHEA trial made it to preprint and submission for peer review, but we will save those discussions for another day.
We read through about 217 medical research abstracts and tracked a queue of preprints on top of that to build this series.
We pulled out the papers that changed something in how we actually practice, then organized them into seven themes. Here is what we think is true now that we did not have the evidence for a year ago.
The series has seven parts. Read in order, or jump to whichever one answers the question you’ve been carrying around this month.
Part 1 — Anti-Amyloid Antibodies Are Narrowing, Not Broadening
Part 2 — Metabolism is the front door: weight-loss drugs, diet, and gut microbes
Part 3 — Movement: what the 2026 exercise data actually says
Part 4 — Long COVID brain fog is chronic, and we finally understand why
Part 5 — Inflammation in the brain is the common thread
Part 6 — Hormones and the brain: timing, form, and how we know
Part 7 — AI in memory care stops being vaporware
